Targeting Glucose Metabolism: An Emerging Concept for Anticancer Therapy
暂无分享,去创建一个
D. Jayne | T. Hughes | S. Perry | David G Jayne | Brijesh M Madhok | Sashidhar Yeluri | Sarah L Perry | Thomas A Hughes | B. Madhok | S. Yeluri
[1] N. Savaraj,et al. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). , 2002, Biochemical pharmacology.
[2] A. Harris,et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .
[3] B. Teicher,et al. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro , 2004, Cancer Chemotherapy and Pharmacology.
[4] P. Sutphin,et al. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy , 2007, Proceedings of the National Academy of Sciences.
[5] Jong-Wan Park,et al. A domain responsible for HIF-1α degradation by YC-1, a novel anticancer agent , 2006 .
[6] R. Shoemaker,et al. Schedule-dependent Inhibition of Hypoxia-inducible Factor-1α Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts , 2004, Cancer Research.
[7] T. Bruno,et al. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. , 1998, Biochemical pharmacology.
[8] G. Semenza. HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. , 2009, Current pharmaceutical design.
[9] Y. J. Sun,et al. The crystal structure of a multifunctional protein: phosphoglucose isomerase/autocrine motility factor/neuroleukin. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[10] T. Hunter,et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[11] M Cascante,et al. The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. , 2001, European journal of biochemistry.
[12] Ching-Shyang Chen,et al. Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells , 2010, Breast Cancer Research and Treatment.
[13] Divya Pathania,et al. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. , 2009, Advanced drug delivery reviews.
[14] G. Melillo,et al. Development of HIF-1 inhibitors for cancer therapy , 2009, Journal of cellular and molecular medicine.
[15] Chi V Dang,et al. Cancer's molecular sweet tooth and the Warburg effect. , 2006, Cancer research.
[16] G. Hart,et al. Glycobiology and Cancer: Meeting Summary and Future Directions , 2004, Cancer biology & therapy.
[17] P. Pedersen. The cancer cell’s “power plants” as promising therapeutic targets: An overview , 2007, Journal of bioenergetics and biomembranes.
[18] R. Gillies,et al. Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.
[19] Jun O. Liu,et al. Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth , 2008, Proceedings of the National Academy of Sciences.
[20] Xiaojun Xu,et al. Transketolase‐like protein 1 (TKTL1) is required for rapid cell growth and full viability of human tumor cells , 2009, International journal of cancer.
[21] Martin G Pomper,et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. , 2004, Biochemical and biophysical research communications.
[22] P. Leder,et al. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.
[23] Hiroshi Yamamoto,et al. Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer. , 1996, British Journal of Cancer.
[24] A. Harris,et al. Targeting the hypoxia-inducible factor (HIF) pathway in cancer , 2009, Expert Reviews in Molecular Medicine.
[25] P. Bottoni,et al. Glycolytic enzyme inhibitors in cancer treatment. , 2008, Expert opinion on investigational drugs.
[26] A. Alavi,et al. Akt Stimulates Aerobic Glycolysis in Cancer Cells , 2004, Cancer Research.
[27] Yinfeng Yang,et al. A new G6PD knockdown tumor-cell line with reduced proliferation and increased susceptibility to oxidative stress. , 2009, Cancer biotherapy & radiopharmaceuticals.
[28] H. Pelicano,et al. Glycolysis inhibition for anticancer treatment , 2006, Oncogene.
[29] R. Wahl,et al. Targeting of VX2 Rabbit Liver Tumor by Selective Delivery of 3-Bromopyruvate: A Biodistribution and Survival Study , 2008, Journal of Pharmacology and Experimental Therapeutics.
[30] G. Paine-Murrieta,et al. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α , 2004, Molecular Cancer Therapeutics.
[31] Min Wu,et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. , 2007, American journal of physiology. Cell physiology.
[32] Y. Liu,et al. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.
[33] A. Raz,et al. Expression and secretion of neuroleukin/phosphohexose isomerase/maturation factor as autocrine motility factor by tumor cells. , 1998, Cancer research.
[34] Jing Chen,et al. Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth , 2009, Science Signaling.
[35] Awtar Krishan,et al. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions , 2004, Cancer Chemotherapy and Pharmacology.
[36] Robert A. Harris,et al. Pyruvate Dehydrogenase Complex Activity Controls Metabolic and Malignant Phenotype in Cancer Cells* , 2008, Journal of Biological Chemistry.
[37] K. Greulich,et al. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. , 2004, Genomics.
[38] N. Savaraj,et al. 2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo , 2004, Cancer Research.
[39] B. Dwarakanath,et al. Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. , 1996, International journal of radiation oncology, biology, physics.
[40] G. Semenza,et al. HIF-1 mediates the Warburg effect in clear cell renal carcinoma , 2007, Journal of bioenergetics and biomembranes.
[41] Saroj P. Mathupala,et al. Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria , 2006, Oncogene.
[42] W. Linehan,et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer , 2009, Molecular Cancer Therapeutics.
[43] J. Pouysségur,et al. MAP Kinases and Hypoxia in the Control of VEGF Expression , 2004, Cancer and Metastasis Reviews.
[44] Ru Wei,et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.
[45] T. Lazar Mathew,et al. Optimizing Cancer Radiotherapy with 2-Deoxy-D-Glucose , 2005, Strahlentherapie und Onkologie.
[46] A. Yalçin,et al. Regulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer. , 2009, Experimental and molecular pathology.
[47] A. Eberle,et al. TT232, A Novel Signal Transduction Inhibitory Compound in the Therapy of Cancer and Inflammatory Diseases , 2005, Journal of receptor and signal transduction research.
[48] J. von Pawel,et al. Phase III trial with and without lonidamine in non-small cell lung cancer. , 1991, Seminars in oncology.
[49] R. Sun,et al. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo , 2010, Breast Cancer Research and Treatment.
[50] Takashi Uehara,et al. Koningic Acid (a Potent Glyceraldehyde‐3‐Phosphate Dehydrogenase Inhibitor)‐Induced Fragmentation and Condensation of DNA in NG108‐15 Cells , 1997, Journal of neurochemistry.
[51] P. Bruzzi,et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Y. Pommier,et al. Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1 , 2004, Cancer Research.
[53] F. Kuhajda,et al. Fatty acid synthase and cancer: new application of an old pathway. , 2006, Cancer research.
[54] Laura C. Greaves,et al. Mitochondrial DNA mutations in human disease , 2006, IUBMB life.
[55] W. Evans,et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. , 2009, Blood.
[56] B. Dwarakanath,et al. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells , 2005, International journal of radiation biology.
[57] R. Wittig,et al. Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. , 2008, American journal of clinical pathology.
[58] B. Silvestrini,et al. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. , 1981, Journal of the National Cancer Institute.
[59] G. Semenza,et al. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.
[60] H. Chen,et al. Overexpression of transketolase-like gene 1 is associated with cell proliferation in uterine cervix cancer , 2009, Journal of experimental & clinical cancer research : CR.
[61] O. Nanni,et al. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial , 1998, Breast Cancer Research and Treatment.
[62] G. Semenza. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. , 1998, Current opinion in genetics & development.
[63] R. Shoemaker,et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition , 2009, Molecular Cancer Therapeutics.
[64] M. Cascante,et al. Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle , 1999, FEBS letters.
[65] N. Munshi,et al. Dichloroacetate induces apoptosis in endometrial cancer cells. , 2008, Gynecologic oncology.
[66] A. Gadducci,et al. Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. , 1994, European journal of cancer.
[67] Sébastien Bonnet,et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. , 2007, Cancer cell.
[68] Chi V Dang,et al. Multifaceted roles of glycolytic enzymes. , 2005, Trends in biochemical sciences.
[69] P. Pedersen,et al. Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers’ most common phenotypes, the “Warburg Effect”, i.e., elevated glycolysis in the presence of oxygen , 2007, Journal of bioenergetics and biomembranes.
[70] A. Scarpa,et al. An integrated humoral and cellular response is elicited in pancreatic cancer by α‐enolase, a novel pancreatic ductal adenocarcinoma‐associated antigen , 2009, International journal of cancer.
[71] P. Pacini,et al. FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results. , 2000, European journal of cancer.
[72] A. Giatromanolaki,et al. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer , 2008, British Journal of Cancer.
[73] S. Kaufmann,et al. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[74] M. Guida,et al. Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study. , 2001, European journal of cancer.
[75] A. Lane,et al. Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation , 2007, Molecular Cancer Therapeutics.
[76] Laurent Schwartz,et al. Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice. , 2009, Anticancer research.
[77] Marta Cascante,et al. Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29 , 2009, International journal of cancer.
[78] John O Trent,et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth , 2008, Molecular Cancer Therapeutics.
[79] M. Knopp,et al. Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor , 2008, Clinical Cancer Research.
[80] C. Hew,et al. Proteomic Analysis of Colorectal Cancer Reveals Alterations in Metabolic Pathways , 2006, Molecular & Cellular Proteomics.
[81] R. Wahl,et al. Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer , 2009, Investigational New Drugs.
[82] N. Savaraj,et al. Differential Sensitivity to 2-Deoxy-D-glucose Between Two Pancreatic Cell Lines Correlates With GLUT-1 Expression , 2005, Pancreas.
[83] N. Savaraj,et al. Hypersensitization of tumor cells to glycolytic inhibitors. , 2001, Biochemistry.
[84] P. Auberger,et al. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells. , 2009, Cancer research.
[85] C. Dang,et al. Oncogenic alterations of metabolism and the Warburg effect , 2005 .
[86] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[87] G. Kéri,et al. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models. , 2006, Anticancer research.
[88] Jong-Wan Park,et al. A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. , 2006, International journal of oncology.
[89] D A Hilton,et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.
[90] R. Deberardinis,et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid β-oxidation , 2005, Oncogene.
[91] L. Leng,et al. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. , 2002, Cancer research.
[92] Jinho Kim,et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. , 2003, Journal of the National Cancer Institute.
[93] Oksana Gavrilova,et al. p53 Regulates Mitochondrial Respiration , 2006, Science.
[94] V. Hogan,et al. Down-regulation of Phosphoglucose Isomerase/Autocrine Motility Factor Expression Sensitizes Human Fibrosarcoma Cells to Oxidative Stress Leading to Cellular Senescence* , 2007, Journal of Biological Chemistry.
[95] D. Scudiero,et al. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.
[96] S. Di Cosimo,et al. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[97] B. Erni,et al. Synthesis of phosphoenol pyruvate (PEP) analogues and evaluation as inhibitors of PEP-utilizing enzymes. , 2002, European journal of biochemistry.